Invitae Corp NVTA

NYS: NVTA | ISIN: US46185L1035   17/04/2024
0,003 USD (+35,00%)
(+35,00%)   17/04/2024

30 januari 2024 · Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics · Persbericht

22 januari 2024 · Invitae Completes Sale of Reproductive Health Assets to Natera · Persbericht

13 december 2023 · Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts · Persbericht

8 november 2023 · Invitae Reports Third Quarter 2023 Financial Results · Persbericht

6 november 2023 · Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships · Persbericht

1 november 2023 · Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 · Persbericht

25 oktober 2023 · Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results · Persbericht

19 oktober 2023 · Invitae Appoints Dr. David Sholehvar as Chief Operating Officer · Persbericht

12 oktober 2023 · Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer · Persbericht

10 oktober 2023 · Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics · Persbericht

3 oktober 2023 · Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization · Persbericht

25 september 2023 · Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO · Persbericht

28 augustus 2023 · Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer · Persbericht

15 augustus 2023 · Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer · Persbericht

14 augustus 2023 · Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO · Persbericht

8 augustus 2023 · Invitae Reports Second Quarter 2023 Financial Results · Persbericht

26 juli 2023 · Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 · Persbericht

31 mei 2023 · Invitae to Present at the William Blair 43rd Annual Growth Stock Conference · Persbericht

26 mei 2023 · New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology · Persbericht

26 mei 2023 · Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO · Persbericht

Mijn selecties